Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

Del Re M, Rofi E, Cappelli C, Puppo G, Crucitta S, Valeggi S, Chella A, Danesi R, Petrini I.

BMC Cancer. 2019 Apr 30;19(1):410. doi: 10.1186/s12885-019-5604-6.

2.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
3.

Would a robot trust you? Developmental robotics model of trust and theory of mind.

Vinanzi S, Patacchiola M, Chella A, Cangelosi A.

Philos Trans R Soc Lond B Biol Sci. 2019 Apr 29;374(1771):20180032. doi: 10.1098/rstb.2018.0032.

4.

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.

Alì G, Bruno R, Poma AM, Affinito O, Monticelli A, Piaggi P, Ricciardi S, Lucchi M, Melfi F, Chella A, Cocozza S, Fontanini G.

Sci Rep. 2019 Mar 5;9(1):3536. doi: 10.1038/s41598-019-40016-8.

5.

The inner speech of the IDyOT: Comment on "Creativity, information, and consciousness: The information dynamics of thinking" by Geraint A. Wiggins.

Chella A, Pipitone A.

Phys Life Rev. 2019 Jan 30. pii: S1571-0645(19)30024-7. doi: 10.1016/j.plrev.2019.01.016. [Epub ahead of print] No abstract available.

PMID:
30738762
6.

Acceptability Study of A3-K3 Robotic Architecture for a Neurorobotics Painting.

Tramonte S, Sorbello R, Guger C, Chella A.

Front Neurorobot. 2019 Jan 10;12:81. doi: 10.3389/fnbot.2018.00081. eCollection 2018.

7.

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Del Re M, Bordi P, Rofi E, Restante G, Valleggi S, Minari R, Crucitta S, Arrigoni E, Chella A, Morganti R, Tiseo M, Petrini I, Danesi R.

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

PMID:
30397287
8.

Medical treatment of malignant pleural mesothelioma relapses.

Petrini I, Lucchesi M, Puppo G, Chella A.

J Thorac Dis. 2018 Jan;10(Suppl 2):S333-S341. doi: 10.21037/jtd.2017.10.159. Review.

9.

Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?

Alì G, Bruno R, Savino M, Giannini R, Pelliccioni S, Menghi M, Boldrini L, Proietti A, Chella A, Ribechini A, Fontanini G.

Arch Pathol Lab Med. 2018 Apr;142(4):480-489. doi: 10.5858/arpa.2017-0135-RA. Epub 2018 Jan 26. Review.

PMID:
29372843
10.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.

J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.

PMID:
29240542
11.

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.

Ambrogi MC, Bertoglio P, Aprile V, Chella A, Korasidis S, Fontanini G, Fanucchi O, Lucchi M, Mussi A.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1857-1866.e2. doi: 10.1016/j.jtcvs.2017.10.070. Epub 2017 Nov 1.

PMID:
29191688
12.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

13.

Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.

Bruno R, Proietti A, Alì G, Puppo G, Ribechini A, Chella A, Fontanini G.

Oncol Lett. 2017 Nov;14(5):5947-5951. doi: 10.3892/ol.2017.6913. Epub 2017 Sep 8.

14.

The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.

Lucchesi M, Sardi I, Puppo G, Chella A, Favre C.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1047-1053. doi: 10.1007/s00280-017-3450-2. Epub 2017 Oct 24. Review.

PMID:
29067473
15.

KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.

Viola D, Giani C, Mazzeo S, Ugolini C, Ciampi R, Molinaro E, Agate L, Borrelli N, Chella A, Fontanini G, Basolo F, Elisei R.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3091-3096. doi: 10.1210/jc.2017-00304.

PMID:
28911147
16.

A Human-Humanoid Interaction Through the Use of BCI for Locked-In ALS Patients Using Neuro-Biological Feedback Fusion.

Sorbello R, Tramonte S, Giardina ME, La Bella V, Spataro R, Allison B, Guger C, Chella A.

IEEE Trans Neural Syst Rehabil Eng. 2018 Feb;26(2):487-497. doi: 10.1109/TNSRE.2017.2728140. Epub 2017 Jul 18.

PMID:
28727554
17.

Reaching and Grasping a Glass of Water by Locked-In ALS Patients through a BCI-Controlled Humanoid Robot.

Spataro R, Chella A, Allison B, Giardina M, Sorbello R, Tramonte S, Guger C, La Bella V.

Front Hum Neurosci. 2017 Mar 1;11:68. doi: 10.3389/fnhum.2017.00068. eCollection 2017.

18.

Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.

Bertoglio P, Ambrogi MC, Chella A, Aprile V, Dini P, Korasidis S, Fanucchi O, Mussi A.

Eur J Surg Oncol. 2017 Jul;43(7):1365-1371. doi: 10.1016/j.ejso.2017.02.010. Epub 2017 Feb 27.

PMID:
28274663
19.

Chest wall resection for mesothelioma recurrence after surgery.

Bertoglio P, Fanucchi O, Ricciardi S, Chella A, Lucchi M, Mussi A.

Asian Cardiovasc Thorac Ann. 2016 Nov;24(9):893-895. Epub 2016 Oct 9.

PMID:
27926466
20.

Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.

Gridelli C, Chella A, Valmadre G, Allegrini G, Brighenti M, Bidoli P, Rossi A, Maione P, Migliorino MR, Ricciardi S, DE Marinis F.

Anticancer Res. 2016 Dec;36(12):6535-6540.

PMID:
27919979
21.

Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.

Alì G, Bruno R, Giordano M, Prediletto I, Marconi L, Zupo S, Fedeli F, Ribechini A, Chella A, Fontanini G.

Oncol Lett. 2016 Nov;12(5):4009-4012. Epub 2016 Sep 26.

22.

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.

Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G.

Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.

23.

Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.

Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R.

Int J Biol Markers. 2017 Mar 2;32(1):e126-e131. doi: 10.5301/jbm.5000229.

PMID:
27646775
24.

First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.

Camerini A, Chella A, Mazzoni F, Puccetti C, Donati S, Lunghi A, Petreni P, Tartarelli G, Serradori M, Di Costanzo F, Amoroso D.

J Chemother. 2017 Feb;29(1):38-41. doi: 10.1080/1120009X.2016.1219498. Epub 2016 Aug 16.

PMID:
27687319
25.

Thrombosis of Kommerell's diverticulum with subclavian steal phenomenon in a patient with non-small cell lung carcinoma under chemotherapy.

Faggioni L, Gabelloni M, Napoli V, Iorio F, Chella A, Caramella D.

Eur J Radiol Open. 2016 Jul 30;3:191-4. doi: 10.1016/j.ejro.2016.07.005. eCollection 2016.

26.

Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction.

Bruno R, Giordano M, Giannini R, Alì G, Puppo G, Ribechini A, Chella A, Fontanini G.

Mol Med Rep. 2016 Sep;14(3):2238-42. doi: 10.3892/mmr.2016.5479. Epub 2016 Jul 7.

PMID:
27430882
27.

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.

Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, Cappuzzo F, Mussi A, Fontanini G.

Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14.

PMID:
27373829
28.

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R.

Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957.

29.

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.

Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.

30.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F.

J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643.

31.

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report.

Alì G, Chella A, Lupi C, Proietti A, Niccoli C, Boldrini L, Davini F, Mussi A, Fontanini G.

Oncol Lett. 2015 Apr;9(4):1537-1540. Epub 2015 Jan 26.

32.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F.

Br J Cancer. 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. Epub 2014 Oct 28.

33.

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.

Rotella V, Fornaro L, Vasile E, Tibaldi C, Boldrini L, Chella A, D'Incecco A, Cirigliano G, Chioni A, Lupi C, Sensi E, Ginocchi L, Giovannelli S, Pennucci MC, Fontanini G, Baldini E.

J Exp Clin Cancer Res. 2014 Oct 11;33:77. doi: 10.1186/s13046-014-0077-6.

34.

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F.

PLoS One. 2014 Aug 19;9(8):e103883. doi: 10.1371/journal.pone.0103883. eCollection 2014.

35.

Physical integration: a causal account for consciousness.

Manzotti R, Chella A.

J Integr Neurosci. 2014 Jun;13(2):403-27. doi: 10.1142/S0219635214400044. Epub 2014 Jun 16.

PMID:
25012716
36.

ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.

Arch Pathol Lab Med. 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. Epub 2014 Jun 2.

PMID:
24885803
37.

Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.

Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F, Miccoli M, Fontanini G.

Cancer Cytopathol. 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. Epub 2014 Mar 19.

38.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.

Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27.

PMID:
24585722
39.

Histo-cytological diagnostic accuracy in lung cancer.

Proietti A, Boldrini L, Alì G, Servadio A, Lupi C, Sensi E, Miccoli M, Ribechini A, Chella A, Lucchi M, Leocata P, Mussi A, Fontanini G.

Cytopathology. 2014 Dec;25(6):404-11. doi: 10.1111/cyt.12117. Epub 2013 Nov 20.

PMID:
24251636
40.

Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).

Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.

J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf.

41.

Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients.

Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, Grassi E, Roncali M, Versari A, Erba PA.

J Thorac Oncol. 2013 Aug;8(8):1095-101. doi: 10.1097/JTO.0b013e318293f051.

42.

Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.

Capodanno A, Boldrini L, Proietti A, Alì G, Pelliccioni S, Niccoli C, D'Incecco A, Cappuzzo F, Chella A, Lucchi M, Mussi A, Fontanini G.

Int J Oncol. 2013 Sep;43(3):765-74. doi: 10.3892/ijo.2013.2003. Epub 2013 Jul 2.

PMID:
23820752
43.

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F.

J Clin Oncol. 2011 Sep 10;29(26):3574-9. doi: 10.1200/JCO.2011.35.9638. Epub 2011 Aug 8.

PMID:
21825258
44.

Self-conscious robotic system design process--from analysis to implementation.

Chella A, Cossentino M, Seidita V.

Adv Exp Med Biol. 2011;718:209-21. doi: 10.1007/978-1-4614-0164-3_17.

PMID:
21744221
45.

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.

J Thorac Oncol. 2011 Sep;6(9):1587-93. doi: 10.1097/JTO.0b013e31821e1c08.

46.

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

Gridelli C, Morgillo F, Favaretto A, de Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F.

Ann Oncol. 2011 Jul;22(7):1528-34. doi: 10.1093/annonc/mdq630. Epub 2011 Jan 6.

PMID:
21212155
47.

Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L.

Int J Biol Markers. 2010 Jul-Sep;25(3):164-70.

PMID:
20878622
48.

Paraneoplastic toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus.

Torchia D, Caproni M, Massi D, Chella A, Fabbri P.

Clin Exp Dermatol. 2010 Jun;35(4):455-6. doi: 10.1111/j.1365-2230.2009.03240.x. No abstract available.

PMID:
20518923
49.

Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?

Lucchi M, Picchi A, Alí G, Chella A, Guglielmi G, Cristaudo A, Fontanini G, Mussi A.

Interact Cardiovasc Thorac Surg. 2010 Apr;10(4):572-6. doi: 10.1510/icvts.2009.223255. Epub 2010 Jan 6.

PMID:
20053697
50.

A robot architecture based on higher order perception loop.

Chella A.

Adv Exp Med Biol. 2010;657:267-83. doi: 10.1007/978-0-387-79100-5_15.

PMID:
20020353

Supplemental Content

Loading ...
Support Center